Focused on immunology-based therapies for infectious diseases, this biotech company reported a notable insider sale in recent ...

(Michael on for Roanna Ruiz), Leerink Partners: "what would constitute a clear signal as a green light to initiate Phase III in 2027?"; President, CEO & Director De Backer: "it's going to really be ...

Discover the role of biotechnology in healthcare, medicine, and investment. Understand biotech processes, top companies, and ...

College of Agriculture, Biotechnology & Natural Resources honors achievement in academics, leadership and research at 2026 ...

Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Bank of America Securities 2026 ...

Automation, AI, and screening technologies are already transforming reproductive medicine. The tools may be accurate, but ...

Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer – Updated Phase 1 ...

PennVet Study to Evaluate GMP-Grade Metformin Eye Drops in a Canine Model Supporting Human and Veterinary Development Pathways ...

Debut Biotech, a company innovating new molecules, is partnering with Image Skincare to launch a new beauty product, CNBC has learned. The San Diego-based company uses biotechnology and artificial ...

Fermentation has evolved from a traditional preservation method into a cornerstone of modern food innovation, where the intersection of bioprocess ...

Is VIR a good stock to buy? We came across a bullish thesis on Vir Biotechnology, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on VIR. Vir Biotechnology, ...